tradingkey.logo

Tango Therapeutics Inc

TNGX
8.700USD
+0.170+1.99%
Close 12/24, 13:00ETQuotes delayed by 15 min
970.63MMarket Cap
LossP/E TTM

Tango Therapeutics Inc

8.700
+0.170+1.99%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Tango Therapeutics Inc

Currency: USD Updated: 2025-12-24

Key Insights

Tango Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.25.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tango Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
46 / 404
Overall Ranking
126 / 4562
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
13.250
Target Price
+38.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tango Therapeutics Inc Highlights

StrengthsRisks
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.22% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 42.07M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 42.07M.
Undervalued
The company’s latest PE is -9.56, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 124.59M shares, increasing 2.16% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 991.96K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.25.

Financial Health

Currency: USD Updated: 2025-12-24

The current financial score of Tango Therapeutics Inc is 8.25, ranking 54/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 53.81M, representing a year-over-year increase of 363.61%, while its net profit experienced a year-over-year increase of 154.46%.

Score

Industry at a Glance

Previous score
8.25
Change
0

Financials

8.25

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

5.33

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.65

Tango Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-12-24

The current valuation score of Tango Therapeutics Inc is 6.19, ranking 327/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.56, which is -90.44% below the recent high of -0.91 and -25.40% above the recent low of -11.98.

Score

Industry at a Glance

Previous score
6.19
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 46/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-24

The current earnings forecast score of Tango Therapeutics Inc is 8.80, ranking 48/404 in the Biotechnology & Medical Research industry. The average price target for Tango Therapeutics Inc is 13.50, with a high of 15.00 and a low of 11.00.

Score

Industry at a Glance

Previous score
8.80
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts
Buy
Current Rating
13.250
Target Price
+38.02%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Tango Therapeutics Inc
TNGX
10
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-24

The current price momentum score of Tango Therapeutics Inc is 6.86, ranking 193/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.40 and the support level at 7.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.66
Change
0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.289
Neutral
RSI(14)
45.578
Neutral
STOCH(KDJ)(9,3,3)
15.401
Neutral
ATR(14)
0.553
High Vlolatility
CCI(14)
-89.801
Neutral
Williams %R
77.528
Sell
TRIX(12,20)
-0.151
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
8.566
Buy
MA10
8.814
Sell
MA20
9.365
Sell
MA50
8.794
Sell
MA100
7.992
Buy
MA200
5.635
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-24

The current institutional shareholding score of Tango Therapeutics Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 94.78%, representing a quarter-over-quarter decrease of 12.11%. The largest institutional shareholder is The Vanguard, holding a total of 5.05M shares, representing 3.75% of shares outstanding, with 4.70% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Farallon Capital Management, L.L.C.
9.16M
+98.59%
EcoR1 Capital, LLC
10.63M
--
Boxer Capital Management, LLC
9.77M
-5.87%
TCG Crossover Management, LLC
10.74M
--
Third Rock Ventures, LLC
14.06M
-10.18%
Woodline Partners LP
6.03M
+1091.24%
Invus Public Equities Advisors, LLC
5.88M
+74.84%
Nextech Invest, Ltd.
5.53M
--
BlackRock Institutional Trust Company, N.A.
4.95M
+32.30%
The Vanguard Group, Inc.
Star Investors
4.03M
+3.90%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-24

The current risk assessment score of Tango Therapeutics Inc is 4.20, ranking 107/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.20
Change
0
Beta vs S&P 500 index
1.75
VaR
+7.57%
240-Day Maximum Drawdown
+67.16%
240-Day Volatility
+114.50%

Return

Best Daily Return
60 days
+18.63%
120 days
+18.63%
5 years
+103.92%
Worst Daily Return
60 days
-13.05%
120 days
-13.05%
5 years
-37.45%
Sharpe Ratio
60 days
+0.53
120 days
+1.60
5 years
+0.38

Risk Assessment

Maximum Drawdown
240 days
+67.16%
3 years
+91.46%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+2.94
3 years
+0.15
5 years
-0.04
Skewness
240 days
+2.53
3 years
+5.11
5 years
+4.60

Volatility

Realised Volatility
240 days
+114.50%
5 years
--
Standardised True Range
240 days
+4.99%
5 years
+6.53%
Downside Risk-Adjusted Return
120 days
+325.07%
240 days
+325.07%
Maximum Daily Upside Volatility
60 days
+57.13%
Maximum Daily Downside Volatility
60 days
+55.84%

Liquidity

Average Turnover Rate
60 days
+2.09%
120 days
+1.95%
5 years
--
Turnover Deviation
20 days
+25.09%
60 days
+72.38%
120 days
+60.76%

Peer Comparison

Biotechnology & Medical Research
Tango Therapeutics Inc
Tango Therapeutics Inc
TNGX
7.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Tango Therapeutics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Tango Therapeutics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Tango Therapeutics Inc’s performance and outlook.

How do we generate the financial health score of Tango Therapeutics Inc?

To generate the financial health score of Tango Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Tango Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Tango Therapeutics Inc.

How do we generate the company valuation score of Tango Therapeutics Inc?

To generate the company valuation score of Tango Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Tango Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Tango Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Tango Therapeutics Inc.

How do we generate the earnings forecast score of Tango Therapeutics Inc?

To calculate the earnings forecast score of Tango Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Tango Therapeutics Inc’s future.

How do we generate the price momentum score of Tango Therapeutics Inc?

When generating the price momentum score for Tango Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Tango Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Tango Therapeutics Inc.

How do we generate the institutional confidence score of Tango Therapeutics Inc?

To generate the institutional confidence score of Tango Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Tango Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Tango Therapeutics Inc.

How do we generate the risk management score of Tango Therapeutics Inc?

To assess the risk management score of Tango Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Tango Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Tango Therapeutics Inc.
KeyAI